 |
|
|
|
|
 |
Last Updated: Nov 1, 2009 - 11:48:48 PM |
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab effective in treating chronic graft-versus-host disease
A study by Dana-Farber Cancer Institute researchers offers the strongest evidence yet of the effectiveness of a novel therapy for chronic graft-versus-host disease (GVHD), a potentially life-threatening complication of donor bone marrow and stem cell transplants.
Mar 24, 2006 - 7:14:37 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab maintenance therapy dramatically improves survival in lymphoma
Two years of maintenance therapy with MabThera (rituximab) dramatically improves the chances of survival for patients suffering from one of the most frequent forms of lymphoma, indolent non-Hodgkins Lymphoma (NHL). The trial showed that the risk of death is halved for patients who receive MabThera maintenance therapy, compared to those who receive no maintenance treatment, irrespective of their initial therapy. We are conscious that these results open a new era in the management of indolent NHL, said William M. Burns, CEO of the Pharmaceuticals Division at Roche. Maintenance therapy with MabThera showed unprecedented survival benefits in a serious cancer disease which is currently considered incurable.
Dec 13, 2005 - 3:35:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab to be Considered for Front-Line Treatment of Intermediate Grade or Aggressive CD-20-positive, B-cell, non-Hodgkin's lymphoma
Genentech, Inc. , Biogen Idec, Inc. and Roche (SWX Zurich) today announced that the companies completed the filing of a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for an additional indication for Rituxan(R) (Rituximab), in previously untreated (front-line) patients with intermediate grade or aggressive, CD-20-positive, B-cell, non-Hodgkin's lymphoma (NHL) in combination with CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or other anthracycline-based chemotherapy regimens.
Aug 18, 2005 - 11:44:38 AM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
DANCER Study shows RA drug rituximab is safe and well-tolerated
In the biggest study of its kind, researchers have shown that the drug rituximab, used to treat rheumatoid arthritis (RA) is safe and effective. The results were presented for the first time today (Thursday 9 June), at the Annual European Congress of Rheumatology, EULAR 2005, in Vienna.
Jun 9, 2005 - 1:25:38 PM
|
Latest Research
:
Pharmacology
:
Anti Cancer Drugs
:
Rituximab
Rituximab may also benefit people with lupus
A drug used to treat cancer may also benefit people with lupus who have complications of the central nervous system. Rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria heard today (Thursday 9 June) that rituximab is the first drug in a quarter of a century that is making a real impact, and an alternative to previous standard treatments of high-dose steroids, and chemotherapy.
Jun 9, 2005 - 1:25:38 PM
|
<< prev
next >>
|
|
|
|
| Health |
Best way to boost adult immunizations is through office-based action, study finds
|
'Pep talk' can revive immune cells exhausted by chronic viral infection
|
Burning more sugar drives super athleticism
|
Research aims to prevent obesity by reaching parents, young children through child care
|
AMD-like lesions delayed in mice fed lower glycemic index diet
|
Low vitamin C levels may raise heart failure patients' risk
|
Sugar-sweetened beverages may increase cardiovascular risk in women
|
Study finds shifting disease burden following universal Hib vaccination
|
UT study: Climate change affects ants and biodiversity
|
Dirt prevents allergy
|
| | Healthcare |
Fitness club memberships help insurance plans to enrol healthier patients
|
Anxiety disorders mount since credit crunch
|
Doctors diagnose patients within moments of meeting
|
Physician-defined patient complexity differs from current diagnosis-based measures
|
Free health screening for school children Nov 14
|
Systematic bias in the assessment of UK doctors
|
White children far more likely to receive CT scans than Hispanic, African-American children
|
Suspected brain disease kills 51 kids in Bihar
|
New rules for bio-medical waste management in India
|
Delhi hospitals lacking in emergency protocols
|
| | Latest Research |
New device performs better than old for removing blood clots
|
Gene related to fat preferences in humans found
|
Cardiovascular Nursing Spring Meeting
|
The effect of occasional binge drinking on heart disease and mortality among moderate drinkers
|
ORNL, partners earn FLC honor for cookstove technology
|
Clot-busting drugs appear safe for treating 'wake-up' stroke patients
|
Infections in childhood linked to high risk of ischemic stroke
|
Penn State scientists elected to American Geophysical Union
|
Wayne State University project aims to reduce HIV, AIDS among African-Americans
|
Scientists help define structure of exoplanets
|
| | Medical News |
Women delivers baby near lift in Noida hospital
|
Obesity on rise in school children: Study
|
Over 10,000 dengue cases in India this year
|
NRI doctors demands removal of 'tainted' medical council members
|
Watch out for sexually transmitted 'superbug': Expert
|
Panel stresses on infection control in hospitals
|
Healthcare cost up 22 times in rural areas, shows study
|
Superbug exists, but nothing alarming: Walia
|
No power problem at AIIMS: Official
|
40 percent Indians embarrassed to ask for contraceptives
|
| | Special Topics |
Behold India's unfolding democratic revolution
|
Chinese woman cuts open her belly to save surgery cost
|
Improved Sense of Smell Produced Smarter Mammals
|
Two-year-old world's first to have extra DNA strand
|
172,155 kidney stones removed from one patient!
|
'Primodial Soup' theory for origin of life rejected in paper
|
Human species could have killed Neanderthal man
|
History, geography also seem to shape our genome
|
3,000 Kerala medical students to attend inter-college meet
|
Tamil Nadu seeks to control deemed universities
|
|
|
